ARID1A-deficient cells require HDAC6 for progression of endometrial carcinoma.
Saved in:
| Title: | ARID1A-deficient cells require HDAC6 for progression of endometrial carcinoma. |
|---|---|
| Authors: | Megino-Luque C; Oncologic Pathology Group, Department of Basic Medical Sciences, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Sisó P; Oncologic Pathology Group, Department of Medicine, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain., Mota-Martorell N; Metabolic Physiopathology Group, Department of Experimental Medicine, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain., Navaridas R; Oncologic Pathology Group, Department of Basic Medical Sciences, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain., de la Rosa I; Oncologic Pathology Group, Department of Medicine, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain., Urdanibia I; Oncologic Pathology Group, Department of Basic Medical Sciences, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain., Albertí-Valls M; Oncologic Pathology Group, Department of Basic Medical Sciences, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Santacana M; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Scientific and Technical Service of Immunohistochemistry, Biomedical Research Institute of Lleida (IRBLleida), Hospital Universitari Arnau de Vilanova, Lleida, Spain., Pinyol M; Oncologic Pathology Group, Department of Basic Medical Sciences, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain.; Department of Pathology, Hospital Universitari Arnau de Vilanova, Lleida, Spain., Bonifaci N; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Molecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain., Macià A; Oncologic Pathology Group, Department of Experimental Medicine, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain., Llobet-Navas D; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Molecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain., Gatius S; Oncologic Pathology Group, Department of Basic Medical Sciences, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Pathology, Hospital Universitari Arnau de Vilanova, Lleida, Spain., Matias-Guiu X; Oncologic Pathology Group, Department of Basic Medical Sciences, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Pathology, Hospital Universitari Arnau de Vilanova, Lleida, Spain.; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, University of Barcelona, Spain., Eritja N; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Oncologic Pathology Group, Department of Medicine, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain. |
| Source: | Molecular oncology [Mol Oncol] 2022 Jun; Vol. 16 (11), pp. 2235-2259. Date of Electronic Publication: 2022 Mar 02. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
